Kiniksa Pharmaceuticals 8-K Filing

Ticker: KNSA · Form: 8-K · Filed: 2025-09-03T00:00:00.000Z

Sentiment: neutral

Topics: disclosure, sec-filing, routine-report

Related Tickers: KNSA

TL;DR

Kiniksa Pharma (KNSA) filed a routine 8-K on 9/3/25, no major news.

AI Summary

Kiniksa Pharmaceuticals International, plc reported on September 3, 2025, that its Class A Ordinary Shares trade under the symbol KNSA on the Nasdaq Global Select Market. The company is incorporated in England and Wales and its principal executive offices are located in London, UK. This filing is a routine current report, indicating no specific material events beyond standard disclosure requirements.

Why It Matters

This 8-K filing serves as a standard disclosure for Kiniksa Pharmaceuticals, confirming its reporting status and listing its Class A Ordinary Shares on the Nasdaq. It does not indicate any new material events.

Risk Assessment

Risk Level: low — This filing is a standard current report with no new material information, thus posing a low risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this Form 8-K filing?

The primary purpose of this Form 8-K filing is to report current information about the company as required by the SEC, specifically noting the date of the earliest event reported as September 3, 2025.

What class of securities is registered and where do they trade?

The Class A Ordinary Shares, with a nominal value of $0.000273235, are registered and trade under the symbol KNSA on The Nasdaq Stock Market LLC (Nasdaq Global Select Market).

Where is Kiniksa Pharmaceuticals International, plc incorporated?

Kiniksa Pharmaceuticals International, plc is incorporated in England and Wales.

What is the principal executive office address for Kiniksa Pharmaceuticals?

The principal executive offices are located at 23 Old Bond Street, Floor 3, London, W1S 4PZ, England, United Kingdom.

Does this filing indicate any specific material events or changes for Kiniksa Pharmaceuticals?

No, this filing appears to be a routine current report and does not specify any new material events or changes beyond standard disclosure requirements.

Filing Stats: 468 words · 2 min read · ~2 pages · Grade level 12 · Accepted 2025-09-03 07:35:17

Key Financial Figures

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On September 3, 2025, Kiniksa Pharmaceuticals International, plc (the "Company") posted an investor presentation (the "Investor Presentation") to its website at investors.kiniksa.com. The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with its planned presentations to investors, analysts and others. A copy of the Investor Presentation is furnished with this Current Report on Form 8-K as Exhibit 99.1.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Kiniksa Pharmaceuticals International, plc Investor Presentation 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC Date: September 3, 2025 By: /s/ Mark Ragosa Mark Ragosa Executive Vice President, Chief Financial Officer

View on Read The Filing